The effect of sunitinib on neuroblastoma and glioblastoma cell growth
| dc.contributor.advisor | Hiss, Donavon | |
| dc.contributor.advisor | Flepisi, Brian | |
| dc.contributor.author | Roos, Kelly | |
| dc.date.accessioned | 2021-03-09T10:36:25Z | |
| dc.date.accessioned | 2024-11-04T13:14:57Z | |
| dc.date.available | 2021-03-09T10:36:25Z | |
| dc.date.available | 2024-11-04T13:14:57Z | |
| dc.date.issued | 2020 | |
| dc.description | Magister Scientiae (Medical Bioscience) - MSc(MBS) | en_US |
| dc.description.abstract | Cancer is a global health catastrophe, with neuroblastoma, the most common solid childhood tumor, and glioblastoma, a deadly brain tumor, being aggressive and unresponsive to current treatment modalities. These tumors are known to utilize uncontrollable cell proliferative capabilities as a mechanism for tumor survival. Therefore, malignant cell growth can be mitigated by targeting the essential proteins that regulate cell growth, such as receptor tyrosine kinases (RTKs). Under normal physiological conditions, RTKs bind with varying affinity to mitogenic stimuli such as growth factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) which, in turn, leads to receptor phosphorylation and activation. | en_US |
| dc.identifier.uri | https://hdl.handle.net/10566/17222 | |
| dc.publisher | University of the Western Cape | en_US |
| dc.rights.holder | University of the Western Cape | en_US |
| dc.subject | Sunitinib | en_US |
| dc.subject | Neuroblastoma | en_US |
| dc.subject | Receptor tyrosine kinases | en_US |
| dc.subject | Tyrosine kinase inhibitors | en_US |
| dc.subject | Vascular endothelial growth factor | en_US |
| dc.title | The effect of sunitinib on neuroblastoma and glioblastoma cell growth | en_US |